https://pharmadog.xyz/news/346967 pharmadog en 2026-08-31T09:00:00.000Z Verily, NVIDIA and NIH launch first multimodal AI model combining EHR and genomics https://pharmadog.xyz/news/346949 pharmadog en 2026-08-31T08:30:00.000Z Radiopharmaceutical experts urge pharma to adopt bolder dosing despite safety concerns https://pharmadog.xyz/news/346947 pharmadog en 2026-08-31T08:30:00.000Z Study reports up to 25% of sampled NFL players had CTE at death, sparking calls for league-wide action https://pharmadog.xyz/news/346948 pharmadog en 2026-08-31T08:30:00.000Z Personalized mRNA melanoma vaccine shows clinical success, reviving optimism for the platform https://pharmadog.xyz/news/346267 pharmadog en 2026-08-31T05:01:00.000Z BMS leverages Celgene merger to revive neuroscience pipeline amid delayed readouts https://pharmadog.xyz/news/346119 pharmadog en 2026-08-31T04:04:00.000Z US biotech edge erodes as China overtakes in trials and research, raising security concerns https://pharmadog.xyz/news/344583 pharmadog en 2026-08-30T18:30:18.000Z FDA approves Mimrylo, a weekly injection for polycythemia vera, developed by Protagonist and sold by Takeda https://pharmadog.xyz/news/344298 pharmadog en 2026-08-30T17:29:05.000Z Alnylam defends its heart failure silencers after AstraZeneca's ATTR-CM trial miss https://pharmadog.xyz/news/343987 pharmadog en 2026-08-30T15:40:30.000Z Arrowhead's RNAi drug Redemplo shows safety advantage over Ionis in late-stage triglyceride trials https://pharmadog.xyz/news/342718 pharmadog en 2026-08-30T07:19:28.000Z AstraZeneca’s oral relaxin drug shows partial success in mid-stage heart-failure trial